Pharmaceutical Technology

APRIL 28, 2023

Ocugen has received orphan drug designation from the US Food and Drug Administration for its OCU410ST (AAV5-hRORA) to treat ABCA4 – linked retinopathies. This condition leads to a gradual deterioration of vision in children.

Food and Drug Administration 52

Food and Drug Administration Transportation FDA Food 52

European Pharmaceutical Review

MARCH 4, 2024

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Food and Drug Administration 89

Food and Drug Administration Transportation FDA Medical 89

Pharmaceutical Technology

MARCH 27, 2023

Food and Drug Administration (FDA) for Lifileucel. The BLA submission for lifileucel, a leading drug candidate of the company, is a step toward in making TIL therapy an option for patients who have progressed following prior treatments. “Our Iovance is pursuing accelerated approval in this indication.

Food and Drug Administration 52

Food and Drug Administration FDA Food Medicine 52

Pharmaceutical Technology

MAY 25, 2023

Celltrion USA has received approval from the US Food and Drug Administration (FDA) for Humira (adalimumab) biosimilar, Yuflyma (adalimumab-aaty) , for multiple indications. It will be offered to patients in prefilled syringe and autoinjector administration options.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

European Pharmaceutical Review

FEBRUARY 21, 2023

SYFOVRE (pegcetacoplan injection) is the first and only treatment approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA), a leading cause of blindness. SYFOVRE is expected to be available by the beginning of March 2023.

FDA 86

FDA Food and Drug Administration Food Leads 86

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Food and Drug Administration 105

Food and Drug Administration Side effects Pharmaceutical Leads 105

European Pharmaceutical Review

FEBRUARY 2, 2024

Biogen’s decision A strategic review of the company’s R&D work evaluated the time and investment required for the post-marketing confirmatory ENVISION study and the likely advancements in the field by the time of potential ADUHELM FDA traditional approval, Biogen explained.

Food and Drug Administration 75

Food and Drug Administration FDA Food Marketing 75

Pharmaceutical Technology

JUNE 12, 2023

Patients with erectile dysfunction (ED) will now be able to access a topical treatment without the need for a prescription after the US Food and Drug Administration (FDA) greenlit Futura Medical’s Eroxon. Shares in Futura Medical rose following the FDA nod – opening 28% higher than the previous day’s (June 9) close.

Food and Drug Administration 52

Food and Drug Administration FDA Prescription Food 52

Pharma Leaders

MAY 18, 2023

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Prospecting 52

Pharmaceutical Technology

JUNE 9, 2023

Rocket Pharmaceuticals has received fast track and orphan drug designations for RP-A601 from the US Food and Drug Administration (FDA) to treat plakophilin-2-related arrhythmogenic cardiomyopathy (PKP2-ACM).

Pharmaceutical 59

Pharmaceutical Food and Drug Administration FDA Food 59

European Pharmaceutical Review

MAY 12, 2023

Innovative therapies for rare diseases The acquisition will help to drive the growth of CTI’s lead product, kinase inhibitor VONJO ® (pacritinib) “in treating myeloproliferative disease,” stated Dr Adam Craig, President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma. The post $1.7b

Food and Drug Administration 100

Food and Drug Administration Biopharma Medicine Food 100

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. The US agency previously granted the Orphan Drug Designation to EDIT-301 for its study in beta thalassemia, in May 2022.

Food and Drug Administration 105

Food and Drug Administration Engineering Patients Food 105

European Pharmaceutical Review

MAY 24, 2023

The US Food and Drug Administration (FDA) has approved the first-ever redosable gene therapy for the rare skin disease dystrophic epidermolysis bullosa (DEB). This can lead to extremely fragile skin that blisters and tears with minor friction or trauma.

Food and Drug Administration 96

Food and Drug Administration Medicine FDA Food 96

European Pharmaceutical Review

OCTOBER 19, 2023

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

Food and Drug Administration 91

Food and Drug Administration Medicine Food Pharmaceutical 91

European Pharmaceutical Review

DECEMBER 22, 2023

This represents a 53 percent premium on Karuna’s closing stock price on 21 December 2023. The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. Under the terms of the deal, BMS will acquire all outstanding shares of Karuna Therapeutics common stock for $330.00

Food and Drug Administration 94

Food and Drug Administration Side effects Safety Food 94

European Pharmaceutical Review

OCTOBER 30, 2023

According to Atamyo Therapeutics, the condition is characterised by progressive muscular weakness, leading to loss of the ability to walk independently. Additionally, these first results were also presented at the 2023 International Limb-Girdle Muscular Dystrophy Conference. At present, there are no curative treatments for LGMD2I/R9.

Food and Drug Administration 89

Food and Drug Administration Safety Food FDA 89

European Pharmaceutical Review

SEPTEMBER 8, 2023

Tirzepatide has been shown… [to lead] to substantial weight loss of, on average, 15 percent over 70 weeks. Final guidance is scheduled to be published on 11 October 2023. The US Food and Drug Administration (FDA) first approved tirzepatide for type 2 diabetes in May 2022.

Food and Drug Administration 96

Food and Drug Administration Medicine Food Manufacturing 96

European Pharmaceutical Review

MARCH 2, 2023

This article explores some of the most notable developments of 2022, and areas that are likely to be a growing focus for data-driven transformation in 2023. EU Clinical Trial Information System From February 2023 all new clinical trials applications must be submitted via the new portal.

Food and Drug Administration 85

Food and Drug Administration Government Management Medicine 85

Pharmaceutical Technology

OCTOBER 12, 2022

This successful outcome for insulin icodec increases the likelihood of achieving Food and Drug Administration (FDA) approval next year, which will establish Novo Nordisk’s dominance in the basal insulin market with the first once-weekly basal insulin therapy.

Food and Drug Administration 72

Food and Drug Administration FDA Marketing Patients 72

European Pharmaceutical Review

AUGUST 22, 2023

The US Food and Drug Administration (FDA)-approved treatment, is the first RSV vaccine indicated for infants from birth to six months of age. US FDA granted approval of Abrysvo to Pfizer Inc. This news follows similar regulatory action by the US FDA in recent months. percent within 90 days after birth.

Food and Drug Administration 82

Food and Drug Administration FDA Government Food 82

European Pharmaceutical Review

OCTOBER 24, 2023

PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides the broadest serogroup coverage of any meningococcal vaccine available in the US for meningococcal disease in individuals aged 10 to 25 years old, has been approved by the US Food and Drug Administration (FDA).

Food and Drug Administration 86

Food and Drug Administration Safety Food FDA 86

European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. What are the trends affecting drug development today?

Food and Drug Administration 84

Food and Drug Administration Manufacturing Pharma Patients 84

European Pharmaceutical Review

AUGUST 18, 2023

“This acceptance of our EU Marketing Authorisation Application is a key milestone in our global effort to help patients living with GA, a leading cause of blindness worldwide. FDA approves first treatment for geographic atrophy Avacincaptad Pegol Avacincaptad pegol (ACP) is a complement C5 protein inhibitor.

Food and Drug Administration 79

Food and Drug Administration Medicine FDA Food 79

Pharmaceutical Technology

AUGUST 24, 2022

The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for iECURE’s GTP-506 to treat Ornithine Transcarbamylase (OTC) deficiency in paediatric patients. A lead product candidate of the company, GTP-506 is a single-dose gene editing therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Food Leads 52

Pharmaceutical Technology

MAY 15, 2023

Trial centres were located across France, Germany, and the United Kingdom with results collected during the 2022-2023 RSV season. Nirsevimab is still undergoing regulatory review in the US, with the US Food and Drug Administration (FDA) accepting the Biologics License Application (BLA) for nirsevimab in January 2023.

Food and Drug Administration 98

Food and Drug Administration Consulting Food FDA 98

European Pharmaceutical Review

JUNE 29, 2023

Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. 1 Nitrosamines are not new or unknown impurities.

Food and Drug Administration 86

Food and Drug Administration Manufacturing Food Medicine 86

Pharmaceutical Technology

APRIL 12, 2023

In March 2023, Joenja secured approval from the US Food and Drug Administration (FDA) to treat the targeted patients. Variants of these genes cause hyperactivity of the PI3Kδ pathway, preventing immune cells from maturing and functioning properly and leading to immunodeficiency and dysregulation.

Food and Drug Administration 59

Food and Drug Administration Patients FDA Food 59

Pharmaceutical Technology

NOVEMBER 7, 2022

A lead product candidate of the company, SNK01 is presently being analysed as a single agent and along with other agents, including checkpoint inhibitors and cell engagers, in trials to treat advanced refractory solid tumours. . “We

Food and Drug Administration 98

Food and Drug Administration Food Networking Safety 98

Pharmaceutical Technology

JUNE 9, 2023

The US Food and Drug Administration (FDA) has granted approval to commence commercial production at Bristol Myers Squibb’s new advanced cell therapy manufacturing facility in Devens, Massachusetts. It intends to combine these two sites into a new building at Cambridge Crossing later in 2023.

Food and Drug Administration 52

Food and Drug Administration FDA Manufacturing Engineering 52

Pharmaceutical Technology

APRIL 19, 2023

While the Clarksville, US-based company completed a Phase Ia study in healthy participants to eventually develop the drug for Alzheimer’s disease, it is likely that the company will now focus on Parkinson’s disease in its Phase II study first, said Kelleher-Andersson. Similarly, research collaborations are also a consideration.

Food and Drug Administration 52

Food and Drug Administration Recruitment Prospecting Food 52

Pharma Leaders

JUNE 20, 2023

F2G has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its new drug application (NDA) for olorofim to treat invasive fungal infections. The NDA was accepted by the regulatory agency for review with a PDUFA target action date set for 17 June 2023.

Food and Drug Administration 52

Food and Drug Administration FDA Food Patients 52

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. The company intends to commercialise Vyjuvek in the US in the third quarter of 2023.

FDA 52

FDA Food and Drug Administration Patients Food 52

European Pharmaceutical Review

NOVEMBER 3, 2023

UK approval of Litfulo follows Europe and US The MHRA authorisation follows approval by the European Medicines Agency (EMA) in September and by the US Food and Drug Administration (FDA) in July 2023.

Food and Drug Administration 85

Food and Drug Administration Side effects Medicine Food 85

Legacy MEDSearch

APRIL 27, 2023

Food and Drug Administration (FDA) for the company’s SIRA RFA Electrosurgical Device (SIRA). Data supporting the breakthrough device designation will be presented at the 24th Annual Meeting for The American Society of Breast Surgeons in Boston, MA on April 26-30, 2023. Are you hiring?

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

European Pharmaceutical Review

JANUARY 9, 2024

Accelerated drug discovery: Simulations and predictive models powered by AI will speed up the drug development process, effectively slashing time to market for drugs. These innovations bestow visual inspection processes with unprecedented precision, identifying imperfections and anomalies that often elude human scrutiny.

Pharmaceutical manufacturing 122

Pharmaceutical manufacturing Manufacturing Pharmaceutical Food and Drug Administration 122

European Pharmaceutical Review

MARCH 6, 2023

Harwell, the UK’s leading science and innovation campus in Oxfordshire will be the location of the Moderna Innovation and Technology Centre (MITC). Construction will begin in 2023. This milestone follows the finalisation of Moderna’s ten-year strategic partnership with the UK government, announced in December 2022.

Manufacturing 83

Manufacturing Food and Drug Administration Government Food 83

Legacy MEDSearch

AUGUST 21, 2023

Food and Drug Administration for its new, advanced Activit-E polyethylene for the Truliant® knee replacement system. Muratoglu invented the first crosslinked polyethylene, and the first of multiple generations of vitamin E, antioxidant polyethylene for leading orthopaedic companies. “We Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Marketing 52